PMID: 7031850Jan 1, 1981Paper

Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy

Scandinavian Journal of Immunology
E ShannonR C Hastings

Abstract

Thalidomide is well documented to be an effective treatment for erythema nodosum leprosum (ENL) occurring in lepromatous leprosy. To be beneficial, thalidomide must interfere with one or more of the several essential steps in the pathogenesis of this syndrome, which is presumed to be a clinical manifestation of an Arthur-type hypersensitivity. Since complexes of antigen and antibody would initiate these events, thalidomide could exert its most direct influence on reactants in this essential step. To determine whether thalidomide affected de novo antibody synthesis, the effect of the drug on the antibody response to sheep erythrocytes in mice was determined. Thalidomide significantly inhibited IgM antibody formation when fed to mice for 5 or 7 days before immunization with sheep erythrocytes. There was also a selective decrease in serum IgM concentrations among leprosy patients being treated with thalidomide for ENL. A clinically relevant site of action of thalidomide in ENL appears to be on the synthesis of IgM antibody. The target site of the drug among the macrophage, antibody-forming, and helper or suppressor lymphocytes remains to be elucidated.

References

Apr 1, 1976·Archives of Dermatology·J T BackeR L Garcia
Feb 1, 1972·Infection and Immunity·S Estrada-Parra
Jan 1, 1974·The American Journal of Tropical Medicine and Hygiene·W E BullockB J Panner
Nov 6, 1965·Lancet·L J Matthews, J R Trautman
Oct 1, 1969·Annals of Internal Medicine·D M Kay, D L Tuffanelli
Jun 1, 1964·The Journal of Clinical Investigation·W F BARTHJ L FAHEY
May 1, 1965·Clinical Pharmacology and Therapeutics·J SHESKIN

❮ Previous
Next ❯

Citations

Jan 1, 1990·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·D HeneyI J Lewis
Jan 1, 1997·Immunopharmacology·E J ShannonF Sandoval
May 1, 1991·British Journal of Haematology·D HeneyD L Barnard
Jan 1, 1995·Clinical and Experimental Dermatology·L MiseryA L Claudy
Apr 15, 2006·Clinical Microbiology Reviews·D M ScollardD L Williams
Aug 14, 2009·Journal of Hematology & Oncology·Venumadhav KotlaAmit Verma
Oct 18, 2001·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·C MeierhoferC J Wiedermann
Dec 1, 1996·Journal of the American Academy of Dermatology·S TsengJ L Shupack
Apr 1, 1989·Journal of Autoimmunity·E CrainD B Drachman
Jan 1, 1988·Fundamental & Clinical Pharmacology·J DescotesJ C Evreux
Feb 1, 1995·Baillière's Clinical Rheumatology·T Gibson
Jan 12, 2012·Journal of Chemotherapy·V Kumar, S Chhibber
Aug 19, 2003·The Annals of Pharmacotherapy·Maria R NascaDennis P West
Oct 30, 2007·Translational Research : the Journal of Laboratory and Clinical Medicine·Edward ShannonMichael Kearney
Apr 24, 2001·Lupus·M Y KarimG R Hughes
Nov 1, 1984·International Journal of Dermatology·E Grosshans, G Illy
Apr 26, 2008·International Reviews of Immunology·Taraneh Paravar, Delphine J Lee
Feb 5, 2013·Expert Review of Hematology·Swati Andhavarapu, Vivek Roy
Mar 1, 1985·International Journal of Dermatology·B Naafs, W R Faber
Mar 10, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·T E ClarkL J Lindsey
Sep 3, 1999·Antimicrobial Agents and Chemotherapy·O Ridoux, M Drancourt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.